ClinicalTrials.gg
Drug

ISIS 304801 clinical trials

Also written ISIS 304801 and Volanesorsen.

studies test it
6
open now
0
in phase 3
4
first study started
2014

How each study uses ISIS 304801 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
3 May 2019 · Waylivra · EMEA/H/C/004538 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

IONIS-APOCIIIRx
3

Development codes

ISIS 304801
5

Other names

Volanesorsen
5

Studies by the year they started

6 studies that test it; most in 2015 (4)

Studies that test ISIS 304801, by start year
YearStudies
20141
20154
20161

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
2
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 5 · Other 1

Ionis Pharmaceuticals, Inc. (3) · Akcea Therapeutics (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)

Studies

Open first, then newest update. How each study uses ISIS 304801 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 6